Shots:

• The P-III GLOW study evaluates Imbruvica + Venclexta/Venclyxto (I+V) vs chlorambucil + obinutuzumab (C+O) in 211 patients in a ratio (1:1) aged ≥65yrs. with CLL/SLL
• The study met its 1EPs of PFS as assessed by IRC & showed a 78% reduction in risk of disease progression or death- mPFS (not reached vs 21mos.) & safety profile of the combination was consistent with the safety profile of monothx. & tolerability profiles were consistent with CLL treatment in a patient population
• The 2EPs includes uMRD (51.9% vs 17.1%) @3mos.- PB uMRD (49% vs 12%) @12mos.- CR rate (38.7% vs 11.4%)- ORR was not different b/w treated groups- time to subsequent therapy was longer for I+V

  | Ref: Abbvie | Image: abbvie